不同HBV基因型慢性乙型肝炎干扰素治疗的临床疗效  

Efficacy of IFN-αfor treating chronic hepatitis B of different HBV genotypes

作　　者：江晓燕[1] 陈明胜[1] 刘宁[1] 

机构地区：[1]福建省福州市传染病医院肝炎科,福州350025

出　　处：《福建医药杂志》2013年第6期78-80,共3页Fujian Medical Journal

摘　　要：目的探讨慢性乙型肝炎不同HBV基因型与干扰素-α(IFN-α)临床治疗之间的应答关系。方法确诊的90例慢性乙型肝炎患者用荧光定量PCR仪器分为B基因型(45例)和C基因型(45例)两组。所有患者均采用IFN-α2b进行治疗,500万U皮下注射,隔日1次,观察至疗程达6个月时。于治疗前、治疗后第3个月及第6个月检测HBV DNA、HBV血清学指标及肝、肾功能,并监测治疗中的不良反应。结果对干扰素治疗的总应答率,B基因型组为40%,C基因型组为20%,B基因型组总应答率高于C基因型组。结论 IFN-α2b抗病毒治疗对HBV B基因型慢性乙型肝炎患者有较好的疗效。Objective To explore the responses of different HBV genotypes to the IFN-α clinical treatment. Methods A total of 90 cases with confirmed diagnosis of chronic hepatitis B were classified into two groups, including HBV genotype B group （45 cases） and HBV genotype C group （45 cases）, with the aid of quantitative PCR instrument. All patients took subcutaneous injection of IFN-α 5 000 000 U every other day, and observed for six months. HBV DNA, HBV serological markers and hepatic and renal function were detected before treatment and in the 3rd and 6th month of treatment, with surveillance of adverse reaction. Results HBV genotypes had different responses to IFN-α treatment. The total response ratio of HBV genotype B, amounting to 40%, was higher than that of HBV genotype C, which was 20%. Conclusion Antiviral therapy of IFN-α has better efficacy on chronic hepatitis B of HBV genotype B.

关 键 词：基因型 慢性乙型肝炎 干扰素-Α 

分 类 号：R512.62[医药卫生—内科学]